Navigation Links
Researchers identify 4 new targets for breast cancer
Date:6/11/2009

HOUSTON - Four suspects often found at the scene of the crime in cancer are guilty of the initiation and progression of breast cancer in mice that are resistant to the disease, a team led by scientists at The University of Texas M. D. Anderson Cancer Center reports in the June edition of Cancer Cell.

"We have a smoking gun" that shows it's no coincidence the three protein receptors and the enzyme that makes them are abnormally expressed in many types of cancer, said Gordon Mills, M.D., Ph.D., professor and chair of M. D. Anderson's Department of Systems Biology and senior author of the paper.

"We've compiled lots of evidence that they are associated with cancer, what's been missing is proof that they could cause cancer," Mills said. "There are no questions left, they should be targeted."

The four are three lysophosphatidic acid (LPA) receptors (LPA1, LPA2, and LPA3) and the LPA-producing enzyme, autotaxin. "Lysophosphatidic acid", Mills said, "is the single most potent known cellular survival factor." LPA binds to a series of G protein-coupled receptors to spark normal cell proliferation, viability, production of growth factors and survival. The Cancer Cell paper shows this powerful network is hijacked to initiate breast cancer and fuel tumor growth, invasion and metastasis.

The team took a strain of mice that is highly resistant to breast cancer and then created four transgenic strains, each strain expressing one of the receptors or autotaxin.

At 24 months, none of the 44 original cancer-resistant mice developed mammary gland cancer. Only one case of inflammation and two cases of a potentially precancerous accumulation of cells known as hyperplasia were noted.

Cancer incidence ranged from 32 percent to 52.8 percent in the four strains of mice with one of the culprit receptors or autotaxin. Invasive and/or metastatic tumors were present to varying degrees, with 45.5 percent of the tumors in the LPA3 strain metastasizing.

A number of drugs are in preclinical development that target the receptors and autotaxin, Mills said. "Now we have transgenic mouse models to test drugs to go forward against these targets."

The four transgenic strains of mice have three unusual characteristics that the team believes make them particularly well-suited as a model of human breast cancer. Unlike most other mouse models, these produce breast cancer that is invasive and metastatic, and some tumors that are estrogen-receptor positive. ER-positive disease is the most common type of breast cancer.


'/>"/>

Contact: Scott Merville
smerville@mdanderson.org
713-792-0661
University of Texas M. D. Anderson Cancer Center
Source:Eurekalert  

Related medicine news :

1. Stanford researchers find culprit in aging muscles that heal poorly
2. UCLA researchers identify markers that may predict diabetes in still-healthy people
3. Mayo Clinic researchers discover new diagnostic test for detecting infection in prosthetic joints
4. Bipolar disorder relapses halved by Melbourne researchers
5. Cell that triggers symptoms in allergy attacks can also limit damage, Stanford researchers find
6. High and mighty: first common height gene identified by researchers behind obesity gene finding
7. Researchers estimate about 9 percent of US children age 8 to 15 meet criteria for having ADHD
8. Majority of 2.4 Million U.S. Children With ADHD Not Diagnosed or Consistently Treated, According to New Gold Standard Study by Cincinnati Childrens Researchers
9. Researchers develop long-lasting growth hormone
10. Jefferson immunology researchers halt lethal rabies infection in brain
11. Purdue researchers develop technology to detect cancer by scanning surface veins
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Researchers identify 4 new targets for breast cancer
(Date:2/9/2016)... Fort Worth, Texas (PRWEB) , ... February 09, ... ... restoration and reconstruction firm helping businesses recover after a disaster, announced today the ... restoration service companies in Hawaii. , “Investing in like-minded companies who ...
(Date:2/9/2016)... Charlotte, NC (PRWEB) , ... February 09, 2016 ... ... support the launch and production of its newest mobility device, the StandUp Walker. ... innovations in walker design in the last 50 years. , StandUp Walker’s novel ...
(Date:2/9/2016)... ... February 09, 2016 , ... Cirracore Enterprise Cloud, today ... workloads to the cloud. Cirracore provides a secure VMware® vCloud Air based ... Internet. Transformation Solutions (TSL Partners) provides a full range of services from ...
(Date:2/9/2016)... FL (PRWEB) , ... February 09, 2016 , ... ... innovative specialty pharmacies, announces today the continuation of the ‘Pay It Forward’ program ... each prescription referral received at our specialty pharmacy. , “Since our Pay ...
(Date:2/9/2016)... ... February 09, 2016 , ... On January 12, 2016 Paul McElwee, ... after they noticed their furnace not producing any heat. Shortly after entering the home, ... heat exchanger was leaking dangerous levels of carbon monoxide into the home, at 2,000 ...
Breaking Medicine News(10 mins):
(Date:2/9/2016)... 9, 2016 QGEN ... den Abschluss eines Kooperationsvertrags mit 10x Genomics ... in den Bereichen Next-Generation-Sequencing (NGS), Single-Cell-Biology und ... Frankfurt Prime Standard: QIA) gab heute den ... die Entwicklung und Förderung umfassender Lösungen in ...
(Date:2/9/2016)... 2016   AllCare Plus Pharmacy announced today ... of Approval ® for Home Care Accreditation ... The Gold Seal of Approval ® is a ... providing safe and effective care.  ... a rigorous on-site survey in January 2016. The survey ...
(Date:2/9/2016)... 9, 2016 The leader in accelerated orthodontics, ... is the recipient of the 2015 Townie Choice ... Class II medical device that speeds up orthodontic tooth ... pain often associated with treatment, AcceleDent was selected by ... annual Orthotown survey of the most reliable ...
Breaking Medicine Technology: